Skip to content

Nuvation Bio NUVB EBITDA margin

EBITDA margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
27.2%-2.2pp
Pfizer logo
PfizerPFE
25.3%
Immunome logo
ImmunomeIMNM
-5,886.7%-11,897pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-164.8%-51.5pp
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-4,637%-5,383pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-174%-78.2pp

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Calculated from Nuvation Bio’s reported figures.

Based on trailing twelve months.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's EBITDA margin?
Nuvation Bio (NUVB) reported EBITDA margin of -103.6% in Q1 2026.
How has Nuvation Bio's EBITDA margin changed year-over-year?
Nuvation Bio's EBITDA margin increased by 98.2% year-over-year, from -5,754.3% to -103.6%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.